NKTR-262 is a novel toll-like receptor (TLR) 7/8 agonist designed to stimulate antigen‐specific immunity against cancer cells.

When NKTR-262 is combined with BEMPEG, which stimulates the production of CD8+ effector T cells, both the innate and adaptive arms of the immune system are activated to fight cancer.

NKTR-262 is specifically engineered using Nektar’s expertise in polymer chemistry for sustained release, to remain confined within the tumor microenvironment, and to minimize the potential for systemic exposure and toxicity.

NKTR-262 is being evaluated in combination with BEMPEG and checkpoint inhibitors in a range of locally advanced or metastatic cancers.



1.    Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy. 2009;1(6):949-964. doi:10.2217/imt.09.70.

2.    Kivimae, S., et al., Journal for ImmunoTherapy of Cancer 2017, 5(Suppl 2):P275

2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

SITC 2018

2018 ESMO Congress

2018 American Association for Cancer Research (AACR) Annual Meeting

Society for Immunotherapy in Cancer (SITC) 32nd Annual Meeting, National Harbor, MD

World Preclinical Congress 2017